TMED3 showed good predictive power in patients with low- and high-stage ccRCC, and low- and high-grade disease in the TCGA cohort and in patients with low- and high-stage cancer in the ICGC cohort (Figure 4, 5). The gene discussed is TMED3; the disease is nonpapillary renal cell carcinoma.